About Daniel Hamstra
The molecular processes that predict who will have a local recurrence after radiation therapy and who will not are not precisely understood. New evidence suggests that prostate tumors with abnormal blood vessel growth (neo-angiogenesis) are more clinically aggressive and likely to recur. The data also suggests that one prominent cellular survival pathway, the PI3K/Akt/mTOR pathway, plays a vital role in prostate cancer and prostate blood vessel resistance to radiation therapy. Dr. Hamstra’s project is focused on developing new treatment strategies that impair blood vessel proliferation and cell growth, and “sterilize” the fast growing tumor via treating patients with new agents that block the PI3K/Akt/mTOR pathway while radiation therapy is being given.
The 2010 Charles Dolan-Mark Walter – PCF Young Investigator Award
Daniel Hamstra, MD, PhD
University of Michigan – Ann Arbor, MI
Kenneth Pienta, MD, Professor, Departments of Internal Medicine and Urology, Associate Dean for Clinical and Translational Research, American Cancer Society Clinical Research Professor, Director, Experimental Therapeutics, Michigan Center for Translational Pathology, Director, Michigan Institute for Clinical and Health Research, at the University of Michigan.